Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Following an argument with her husband, who is a Daman Coast Guard officer, a 29-year-old woman allegedly threw her two children, aged two and three, off the balcony of their fourth-floor house ...

OLA Experience Centre, Vapi 8033113311 H.N 17/C, Shop #4/5, Ringanwada, Daman, Daman and diu, 396215 Royal Thumpers 9619182872 Ringanwada Shop No 16/17, Rasraj Appartment, Daman, Daman and diu, 396210 ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

What is the current diesel price in Daman? As of today, Sunday, January 26, 2025, the price of 1 litre of diesel in Daman is ₹87.87 per litre. What was the diesel price in Daman yesterday?

Zydus Lifesciences has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b trial testing its experimental oral treatment usnoflast in people with amyotrophic lateral ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral Sclerosis (ALS), a rare neurodegenerative disease. New Delhi, Jan 22 (PTI) Zydus ...

Zydus Lifesciences made headlines on Wednesday as the US health regulator bestowed Orphan Drug Designation upon Usnoflast, their developing treatment for amyotrophic lateral sclerosis (ALS). The US ...